登革热和黄热病疫苗接种对四价登革热疫苗在人体中的免疫原性、感染力和安全性的预充效应。
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
机构信息
Microbiology and Infectious Diseases, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia.
出版信息
Am J Trop Med Hyg. 2011 Oct;85(4):724-31. doi: 10.4269/ajtmh.2011.10-0436.
Abstract
A dengue vaccine effective against all four serotypes is urgently needed. However, safety and immunogenicity could be affected by prior exposure to flaviviruses. This open, controlled, phase IIa study was conducted in 35 healthy adults who had received monovalent, live attenuated Vero cell-derived dengue vaccine against dengue virus 1 (VDV1) or 2 (VDV2) or yellow fever (YF) vaccine 1 year before or who were flavivirus-naïve. All participants received one subcutaneous injection of tetravalent dengue vaccine (TDV) and were followed for 180 days. Previous vaccination did not increase reactogenicity, laboratory abnormalities, or incidence of vaccine viremia, but it did increase the neutralizing antibody response to dengue virus that persisted at day 180. There was no increase in YF antibodies in participants previously immunized with YF vaccine. Prior exposure to YF or monovalent dengue vaccines had no adverse effects on the safety or incidence of viremia associated with this TDV, but it increased immunogenicity.
摘要
急需一种能有效针对所有 4 种血清型的登革热疫苗。然而，先前暴露于黄病毒可能会影响安全性和免疫原性。这项开放、对照、2a 期研究在 35 名健康成年人中进行，这些成年人在 1 年前接种过单价、减毒活vero 细胞来源的登革热 1 型（VDV1）或 2 型（VDV2）疫苗或黄热病（YF）疫苗，或为黄病毒初免者。所有参与者均接受一剂四价登革热疫苗（TDV）的皮下注射，并随访 180 天。既往接种不会增加疫苗接种后的不良反应、实验室异常或疫苗病毒血症的发生率，但会增加对登革热病毒的中和抗体反应，这种反应持续到第 180 天。先前接种 YF 疫苗的参与者中，YF 抗体没有增加。先前接触 YF 或单价登革热疫苗不会对与这种 TDV 相关的安全性或病毒血症发生率产生不利影响，但会增加免疫原性。
相似文献
1
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.登革热和黄热病疫苗接种对四价登革热疫苗在人体中的免疫原性、感染力和安全性的预充效应。
Am J Trop Med Hyg. 2011 Oct;85(4):724-31. doi: 10.4269/ajtmh.2011.10-0436.
2
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.采用加速免疫程序的 CYD 四价登革热疫苗的免疫原性：美国成年人的随机 2 期研究。
BMC Infect Dis. 2018 Sep 21;18(1):475. doi: 10.1186/s12879-018-3389-x.
3
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.减毒活嵌合黄热2型登革热疫苗（ChimeriVax-DEN2）：安全性和免疫原性的I期临床试验：黄热预免疫对诱导针对所有4种登革热血清型的交叉中和抗体反应的影响。
Hum Vaccin. 2006 Mar-Apr;2(2):60-7. doi: 10.4161/hv.2.2.2555. Epub 2006 Mar 15.
4
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.在墨西哥无黄病毒感染史的成年人中评估二价和四价登革热疫苗制剂。
Hum Vaccin Immunother. 2014;10(10):2853-63. doi: 10.4161/21645515.2014.972131.
5
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.一种嵌合黄热病 - 登革热病毒四价疫苗在非人灵长类动物中的构建、安全性及免疫原性
J Virol. 2001 Aug;75(16):7290-304. doi: 10.1128/JVI.75.16.7290-7304.2001.
6
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.墨西哥城登革热易感儿童、青少年及成人中四价减毒活登革热疫苗：安全性和免疫原性的随机对照1期试验
Pediatr Infect Dis J. 2011 Jan;30(1):e9-17. doi: 10.1097/INF.0b013e3181fe05af.
7
Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.四价黄热病-登革热嵌合疫苗在非人灵长类动物中的病毒血症和免疫原性：基因重组、剂量调整及针对野生型登革病毒分离株的抗体反应
Virology. 2002 Jun 20;298(1):146-59. doi: 10.1006/viro.2002.1462.
8
Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.在哥伦比亚和秘鲁12至13个月大的健康幼儿中，黄热病疫苗（Stamaril）与一种四价登革热候选疫苗同时接种时的免疫原性和安全性：一项随机试验。
Pediatr Infect Dis J. 2016 Oct;35(10):1140-7. doi: 10.1097/INF.0000000000001250.
9
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.减毒登革热病毒疫苗（安万特巴斯德公司生产）在人类志愿者中的安全性和免疫原性。
Vaccine. 2001 Apr 30;19(23-24):3179-88. doi: 10.1016/s0264-410x(01)00020-2.
10
Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.在亚洲和拉丁美洲儿童中，武田公司的四价登革热疫苗一剂与两剂的安全性和免疫原性：一项 2 期、随机、安慰剂对照研究的中期结果。
Lancet Infect Dis. 2017 Jun;17(6):615-625. doi: 10.1016/S1473-3099(17)30166-4. Epub 2017 Mar 30.
引用本文的文献
1
'Mix and Match' vaccination: Is dengue next?“混搭”接种疫苗：下一个是登革热吗？
Vaccine. 2022 Oct 26;40(45):6455-6462. doi: 10.1016/j.vaccine.2022.09.007. Epub 2022 Oct 1.
2
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.用于应对人畜共患病和新出现的公共卫生威胁的病毒载体疫苗的开发与应用。
Vaccines (Basel). 2020 Nov 13;8(4):680. doi: 10.3390/vaccines8040680.
3
Anti-dengue Vaccines: From Development to Clinical Trials.抗登革热疫苗：从研发到临床试验。
Front Immunol. 2020 Jun 18;11:1252. doi: 10.3389/fimmu.2020.01252. eCollection 2020.
4
A review of Dengvaxia®: development to deployment.登革热疫苗（Dengvaxia®）：从研发到应用的综述。
Hum Vaccin Immunother. 2019;15(10):2295-2314. doi: 10.1080/21645515.2019.1658503. Epub 2019 Oct 7.
5
Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?互补型初免-加强免疫策略能否成为抗登革病毒的一种替代且有前景的疫苗接种方法？
Front Immunol. 2019 Aug 27;10:1956. doi: 10.3389/fimmu.2019.01956. eCollection 2019.
6
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.在新加坡和越南健康人群中四价登革热疫苗（CYD-TDV）的长期免疫原性和安全性：随机、对照、II 期试验的 4 年随访。
Hum Vaccin Immunother. 2019;15(10):2315-2327. doi: 10.1080/21645515.2019.1578595. Epub 2019 Mar 20.
7
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).登革热血清流行率：来自14个国家（2005 - 2014年）四价登革热疫苗临床开发的数据。
Trans R Soc Trop Med Hyg. 2018 Apr 1;112(4):158-168. doi: 10.1093/trstmh/try037.
8
Prevention and Control Strategies to Counter Dengue Virus Infection.应对登革病毒感染的预防与控制策略
Front Cell Infect Microbiol. 2017 Jul 25;7:336. doi: 10.3389/fcimb.2017.00336. eCollection 2017.
9
Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.哪种登革热疫苗方法最有前景，我们是否应该担心接种疫苗后的增强疾病？登革热疫苗研发和实施引发的问题：赛诺菲巴斯德四价登革热疫苗为例。
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):a029462. doi: 10.1101/cshperspect.a029462.
10
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.接种四价登革热疫苗后长达 4 年的免疫原性综合分析。
Hum Vaccin Immunother. 2017 Sep 2;13(9):2004-2016. doi: 10.1080/21645515.2017.1333211. Epub 2017 Jun 9.
本文引用的文献
1
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.墨西哥城登革热易感儿童、青少年及成人中四价减毒活登革热疫苗：安全性和免疫原性的随机对照1期试验
Pediatr Infect Dis J. 2011 Jan;30(1):e9-17. doi: 10.1097/INF.0b013e3181fe05af.
2
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.一种新型四价登革热疫苗在黄病毒初免成人中具有良好的耐受性和针对所有 4 种血清型的免疫原性。
J Infect Dis. 2010 Feb 1;201(3):370-7. doi: 10.1086/649916.
3
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.基于黄热病 17D 疫苗的嵌合疫苗在登革热、西尼罗河和日本脑炎病毒防治方面的临床前和临床研究进展。
Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4.
4
Evaluation of interferences between dengue vaccine serotypes in a monkey model.在猴模型中评估登革热疫苗血清型之间的干扰作用。
Am J Trop Med Hyg. 2009 Feb;80(2):302-11.
5
Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.在初次接触或黄病毒致敏的受试者中，嵌合四价登革热疫苗诱导的细胞介导免疫。
Vaccine. 2008 Oct 23;26(45):5712-21. doi: 10.1016/j.vaccine.2008.08.019. Epub 2008 Aug 30.
6
Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines.用于定量黄热病和嵌合黄热病-登革热疫苗的标准化定量逆转录聚合酶链反应检测法。
J Virol Methods. 2008 Jul;151(1):40-6. doi: 10.1016/j.jviromet.2008.03.026. Epub 2008 May 22.
7
Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.登革病毒人源抗体噬斑减少中和试验指南
Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007.
8
Dengue hemorrhagic fever with special emphasis on immunopathogenesis.登革出血热，特别强调免疫发病机制。
Comp Immunol Microbiol Infect Dis. 2007 Sep;30(5-6):329-40. doi: 10.1016/j.cimid.2007.05.010. Epub 2007 Jul 23.
9
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.减毒活嵌合黄热2型登革热疫苗（ChimeriVax-DEN2）：安全性和免疫原性的I期临床试验：黄热预免疫对诱导针对所有4种登革热血清型的交叉中和抗体反应的影响。
Hum Vaccin. 2006 Mar-Apr;2(2):60-7. doi: 10.4161/hv.2.2.2555. Epub 2006 Mar 15.
10
Immunopathological mechanisms in dengue and dengue hemorrhagic fever.登革热和登革出血热的免疫病理机制。
Curr Opin Infect Dis. 2006 Oct;19(5):429-36. doi: 10.1097/01.qco.0000244047.31135.fa.
Zotero 插件